⟵ Back to Search Results

BGB-A317-A1217-202 AdvanTIG-202

Active, not recruiting

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Beigene Study ID info

BGB-A317-A1217-202 AdvanTIG-202

ClinicalTrials.gov ID info

NCT04693234

EudraCT Number info

2020-004657-77

Study Overview

Sex: Female

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents

Study Overview

Sex: Female

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents